Biotek-snakken — Februar 2025
-
Medix has resubmitted tesofensine application to COFEPRIS
Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces that its partner Medix has resubmitted the tesofensine application dossier to COFEPRIS, as referenced in Saniona’s press release dated February 10.
"I congratulate the Medix team on this significant achievement. Following feedback from COFEPRIS, they have updated and resubmitted the complete tesofensine dossier - approximately 20,000 pages - addressing al
-
Den godkendelsesproces med Tesofensine er en historie der vel kan sammenlignes med Frodos rejse igennem Mordor for at få smidt ringen ned i vulkanen (Directors Cut) Det begynder at trække i retning af en godkendelse af Tesofensine. Det vil i hvert fald være mærkeligt, hvis det ender med et afslag efter den seneste tid, hvor der tilsyneladende har været et tæt samarbejde imellem Medix og Cofepris forat få afsluttet godkendelsesprocessen. Så kan spørgsmålet være om hvor lang tid det skal tage
...
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind